Amgen obtains licence for preparation for osteoporosis
The US company, which supports a German research unit in BioPark Regensburg, reported in its latest press release that new levels of knowledge in bone biology have led the way to finding an important protein. This is essential in the complex interplay for regular renewal of the bone matrix and leads with erroneous regulation to the feared condition of osteoporosis. The antibody developed by Amgen and now licensed in the in the USA and Europe is manufactured via genetic technology and is highly selective in its efficacy. Its therapeutic use will initially be in the treatment of osteoporosis in women post-menopause with an increased risk of bone fractures and osteoporosis in men, caused by hormone treatment in prostate cancer. According to the World Health Organisation (WHO) 40% of women suffer in the course of their life from osteoporosis. The costs of osteoporosis patients in Europe currently at 36 billion is estimated to increase yearly to 77 billion by 2050. Experts expect that in the future the new process could be used in rheumatoid arthritis and in bone metastases.
For more information see: